Loading..

Northwest Biotherapeutics, Inc. (NWBO) Report Analysis

Corporate Events

Neutral

Northwest Biotherapeutics, Inc. Presents at The...

2022-06-06 01:52:00

Northwest Biotherapeutics, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-03-2022 . Venue: McCormick Place, Chicago, Illinois, United Stat...

Positive

Northwest Biotherapeutics Announces MHRA Approv...

2021-12-21 14:24:00

Northwest Biotherapeutics announced that approval has been received from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of ...

Neutral

American Society Of Clinical Oncology, Inc., th...

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago,...

Positive

Northwest Biotherapeutics, Inc. Enters into A L...

2021-11-29 21:30:00

On November 22, 2021, Northwest Biotherapeutics, Inc. entered into a loan financing with Streeterville Capital, LLC (the Lender") pursuant to ...

Positive

Northwest Biotherapeutics, Inc. announced that ...

2021-11-22 00:00:00

Northwest Biotherapeutics, Inc announced that it has entered into a loan financing with Streeterville Capital, LLC for gross proceeds of $15,0...

Positive

Northwest Biotherapeutics Announces Hta License...

2021-10-28 15:42:00

Northwest Biotherapeutics, Inc. announced the completion of two key milestones which are required for production of DCVax products at the Comp...

Neutral

Northwest Biotherapeutics, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-03-2022

2022-06-06 01:52:00

Northwest Biotherapeutics, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-03-2022 . Venue: McCormick Place, Chicago, Illinois, United States. Speakers: Marnix L. Bosch, Chief Technical Officer.

Positive

Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing at Sawston, UK Facility

2021-12-21 14:24:00

Northwest Biotherapeutics announced that approval has been received from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of a license for manufacture of GMP (clinical grade) cell therapy products at its Sawston, UK facility. The MHRA license approval enables the manufacturing of DCVax-L products to get under way at the Sawston facility in addition to continuing at the smaller GMP facility in London. The license also permits the import and GMP manufacture of other cell therapy products under the UK's supply of unlicensed medicinal products ('Specials') regime and for clinical trials under the Investigational Medicinal Products (IMP) Programme. The Company is developing the Sawston facility in phases, both to optimize the timing of capital requirements and to enable each phase to be when developed, as manufacturing technologies are advancing significantly in the field of cell therapies. To date, the Company has developed Phase 1A of the facility, comprising approximately 4,400 square feet of the overall 88,345 square feet. The Company anticipates that Phase 1A alone will be able to manufacture DCVax-L products for 45-50 patients per month, or 450-500 patients per year – a significant increase from the current manufacturing capacity of four to six patients per month which, to date, has been taking place in a GMP clean room facility in London, UK. This MHRA license is a culmination of intensive preparations that have been underway for much of 2021. The process included an extensive application process, a week-long inspection of all aspects of the physical facility, its construction and equipment, all aspects of the facility's operations, including all operating systems, flow of materials and activities, sterility, quality control, staff and other factors, and all of the regulatory documentation, including standard operating procedures (SOPs) for the facility and for the product, batch manufacturing records, data from practice manufacturing runs and other required documents. This MHRA license follows the license approval by the UK'sHuman Tissue Authority (HTA) in October. That license covers the collection, processing and storage of human tissue and cells for medical purposes, including cell therapies such as DCVax-L. The preparatory work and applications for the MHRA and HTA licenses have been carried out by Advent Bioservices, NWBio's UK entity contract manufacturer, operator, and license holder.

Neutral

American Society Of Clinical Oncology, Inc., the 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago, Illinois, United States.

Positive

Northwest Biotherapeutics, Inc. Enters into A Loan Financing with Streeterville Capital, LLC

2021-11-29 21:30:00

On November 22, 2021, Northwest Biotherapeutics, Inc. entered into a loan financing with Streeterville Capital, LLC (the Lender") pursuant to which the Company received net proceeds of $15,000,000. The Loan has a maturity of 22 months. No payments are due for the first 8 months of the Loan term. Thereafter, the Loan will be amortized in 14 equal monthly installments of principal at 110% of the pro rata amount, plus accrued interest. The interest on the Loan is 8% per annum, and there is a 10% OID. The Loan allows pre-payment at any time at the Company's election. The Loan documents contain customary default provisions. Upon announcement of the top line data (TLD") from the Company's Phase III clinical trial of DCVax -L for glioblastoma brain cancer, the Lender has a then-springing right to exchange the outstanding balance of the loan for common shares priced at the price of the first private placement transaction following TLD less a 12% discount and to purchase another 50% of that number of shares at the same price. This then-springing right expires 14 days after the post-TLD private placement.

Positive

Northwest Biotherapeutics, Inc. announced that it has received $15 million in funding from Streeterville Capital, LLC

2021-11-22 00:00:00

Northwest Biotherapeutics, Inc announced that it has entered into a loan financing with Streeterville Capital, LLC for gross proceeds of $15,000,000 on November 22, 2021. The interest on the loan is 8% per annum and there is 10% original issue discount. The loan has a maturity of 22 months. No payments are due for the first 8 months of the loan term. The loan allows pre-payment at any time at the company's election. The loan will be amortized in 14 monthly equal installments of principal at 110% of the pro rata amount, plus accrued interest. The investor has a then-springing right to exchange the outstanding balance of the loan for common shares priced at the price of the first transaction following top line data less a 12% discount and to purchase another 50% of that number of shares at the same price. This then-springing right expires 14 days after the post- top line data transaction.

Positive

Northwest Biotherapeutics Announces Hta License Issued and Mhra Inspection Conducted for Sawston, UK Facility

2021-10-28 15:42:00

Northwest Biotherapeutics, Inc. announced the completion of two key milestones which are required for production of DCVax products at the Company's manufacturing facility in Sawston, UK, and which have been a major focus since the completion of initial construction last year. First, a license to work with human tissues for medical products at Sawston has been issued by the UK Human Tissue Authority to the company's contract manufacturer and operator of the facility, Advent BioServices. Second, the comprehensive regulatory inspection of the facility has been conducted by the UK Medicines and Health Products Regulatory Authority. In the UK, an HTA license is required for the collection, processing and storage of human tissues and cells for medical purposes. This includes the tumor tissues used to prepare the lysate for DCVax-L products, and the immune cells that comprise the active ingredient of DCVax-L. Obtaining such a license requires an application, inspection and certification process. This process has now been completed and the HTA license allowing the relevant activities to be conducted at Sawston for DCVax-L has been issued. The Sawston facility must also be certified and licensed by MHRA in order to be able to manufacture products such as DCVax-L. The process involves an extensive application process, comprehensive inspection of all aspects of the physical facility, its construction and equipment, and all aspects of the facility's operations, including all operating systems, flow of materials and activities, sterility, quality control, staffing and other factors. It also includes extensive scrutiny of the quality management system that comprises approximately 1,000 regulatory documents, including standard operating procedures for the facility and for the product, validation records, data from practice manufacturing runs and other required documents. Intensive preparations have been under way all year for this comprehensive inspection. A detailed application package and data were submitted to MHRA to qualify for the inspection. The original inspection timing was delayed by MHRA due to their caseload; however, the week-long onsite review by two MHRA inspectors was recently completed. The final phase of the process involves receiving an official MHRA inspection report and taking any responsive actions that may be required. The Company currently anticipates that this process will be completed before year-end.

Fundamental Summary

Northwest Biotherapeutics released impressive Q1 results on 2022-05-10. Their growth and income factors performance indicate that company management is focused on the right targets and executing well. We expect that this positive performance will continue in the coming months, and anticipate that Northwest Biotherapeutics will maintain good momentum even in a challenging environment. Therefore, they earned a total score of 77 out of 100 and a HOLD recommendation.

Northwest Biotherapeutics reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 0.403 million compared to USD 0.239 million a year ago. Net loss was USD 14.21 million compared to USD 4.12 million a year ago. Basic loss per share from continuing operations was USD 0.01. Diluted loss per share from continuing operations was USD 0.01.

Business Description

Northwest Biotherapeutics, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Sector Overview

Northwest Biotherapeutics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Northwest Biotherapeutics's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 30.7 -23.7% 63
Liabilities 151.2 -7.9% 65
Price to Book -5.5 -1.8% 86
Cash & Equivalents 7.0 -54.1% 38
Equity -120.5 2.8% 48
EBITDA -44.2 13.9% 90
Total Revenues 1.2 16.3% 43
Parameter Value Change Score
Return on Equity -71.4 3.0% 65
Net Cashflow -0.5 -109.7% 80
Capital Expenditure -5.8 3.4% 81
Asset Turnover 0.0 34.6% 86
Free Cashflow -0.0 4.5% 77

* All values are TTM

The below chart reflects Northwest Biotherapeutics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Northwest Biotherapeutics's peer average final assessment score stands on 64.0, Northwest Biotherapeutics's score is 77.

  •  NWBO
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 0 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 1 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 2 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 3 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 4 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 5 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 6 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 7 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 8 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 9 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 10 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 11 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 12 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 13 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 14 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 15 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 16 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 17 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 18 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 19 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 20 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 21 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 22 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 23 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 24 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 25 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 26 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 27 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 28 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 29 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 30 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 31 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 32 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 33 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 34 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 35 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 36 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 37 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 38 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 39 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 40 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 41 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 42 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 43 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 44 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 45 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 46 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 47 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 48 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 49 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 50 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 51 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 52 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 53 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 54 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 55 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 56 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 57 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 58 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 59 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 60 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 61 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 62 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 63 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 64 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 65 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 66 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 67 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 68 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 69 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 70 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 71 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 72 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 73 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 74 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 75 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 76 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 77 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 78 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 79 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 80 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 81 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 82 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 83 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 84 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 85 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 86 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 87 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 88 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 89 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 90 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 91 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 92 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 93 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 94 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 95 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 96 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Northwest Biotherapeutics's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Northwest Biotherapeutics's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 37.

Bearish 37
Close Price 0.67
52W Low 0.6
52W High 1.91
5D MA 0.68
50D MA 0.86
200D MA 0.91
MACD -0.04
RSI 0.64
STOCH 60.05

Balance Sheet Analysis

Two main balance sheet metrics are driving the positive outlook for Northwest Biotherapeutics's financial strength going forward. Northwest Biotherapeutics publishes impressive results related to book value factors in this report. Specifically, price to book ratio (P/B) now sits at -5.5 and represents a -1.8% change from the previous report. Their industry-leading book value factors momentum reinforces an expectation for future positive momentum for their stock price going forward. The company's book value factors component, therefore, received a grade of 86. Also, Northwest Biotherapeutics has done an excellent job managing its liabilities. Northwest Biotherapeutics's liabilities stood at 151.2 in the current filing, which represents a -7.9% change from the previous report. This performance is all interesting relative to their peers and suggests that their stock price has room to grow to reflect a higher intrinsic value. The company's liabilities movement component, therefore, received a grade of 65. However, one discouraging result, Cash & Equivalents, stood out. Northwest Biotherapeutics reported concerning cash and cash equivalents metrics in this filing. Specifically, they reported that cash and cash equivalents were 7.0, representing a -54.1% change from the last period. The company's cash and cash equivalents metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Its cash and cash equivalents movement, therefore, received a grade of 38. Therefore, we scored its balance sheet a 65.

Parameter Value Change Score
Assets 30.7 -23.7% 63
Liabilities 151.2 -7.9% 65
Price to Book -5.5 -1.8% 86
Cash & Equivalents 7.0 -54.1% 38
Equity -120.5 2.8% 48
* All values are TTM

The below chart describes Northwest Biotherapeutics's performance as reflected on its balance sheet with respect to its peers. While Northwest Biotherapeutics received a balance sheet score of 65, the average of its peers stands on 61.0.

  •  NWBO
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 0 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 1 1
Amgen Inc. 130.1B 72 68 86 53 62 69 2 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 3 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 4 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 5 1
BioNTech SE 34.0B 75 69 64 97 73 75 6 1
Seagen Inc. 32.9B 59 68 55 43 66 61 7 1
Biogen Inc. 29.7B 57 72 92 50 76 76 8 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 9 1
Incyte Corporation 16.8B 71 72 95 82 79 83 10 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 11 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 12 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 13 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 14 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 15 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 16 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 17 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 18 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 19 1
Alkermes plc 5.0B 63 66 46 54 71 62 20 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 21 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 22 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 23 1
Natera, Inc. 3.6B 73 65 43 95 42 54 24 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 25 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 26 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 27 1
CureVac N.V. 2.6B 49 64 75 52 52 57 28 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 29 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 30 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 31 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 32 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 33 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 34 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 35 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 36 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 37 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 38 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 39 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 40 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 41 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 42 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 43 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 44 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 45 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 46 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 47 1
CareDx, Inc 1.2B 54 67 52 39 51 52 48 1
Vericel Corporation 1.1B 51 65 56 53 61 57 49 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 50 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 51 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 52 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 53 1
MannKind Corporation 957.2M 79 59 50 40 64 57 54 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 55 1
Merus N.V. 941.6M 59 68 50 83 81 70 56 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 57 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 58 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 59 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 60 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 61 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 62 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 63 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 64 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 65 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 66 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 67 1
Geron Corporation 566.2M 69 72 37 59 62 60 68 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 69 1
Immatics N.V. 538.7M 56 70 84 95 73 76 70 1
Agenus Inc. 520.5M 73 62 37 55 60 54 71 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 72 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 73 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 74 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 75 1
Affimed N.V. 415.0M 56 66 63 56 47 54 76 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 77 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 78 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 79 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 80 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 81 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 82 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 83 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 84 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 85 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 86 1
AC Immune SA 299.8M 84 64 47 53 75 68 87 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 88 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 89 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 90 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 91 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 92 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 93 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 94 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 95 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 96 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 97 1

Income Statement Analysis

Northwest Biotherapeutics appears likely to maintain its strong income statement metrics and momentum going forward. Northwest Biotherapeutics's management was effective in improving its EBIDTA, which now sits at -44.2 and represents a 13.9% change from the last reporting period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Their EBITDA metrics are even more impressive relative to their peers and competitors, and its likely the stock price has room to grow to reflect its intrinsic value accurately. Therefore, its EBITDA component earned a score of 90. Also, Return factors metrics and ratios were exceptional in this report. Northwest Biotherapeutics reported a return on equity (ROE) ratio of -71.4, representing a change of 3.0% from the last report. The company appears headed in the right direction in terms of these return factors, exhibiting prudent capital expenditure growth compared to its peers. Consequently, their return factors received a grade of 65. On the other hand, Revenue Efficiency, jumped out as looking rather underwhelming. Northwest Biotherapeutics management did an underwhelming job managing revenue efficiency this past period. Northwest Biotherapeutics's revenue efficiency is 1.2 according to the metrics in the current filing, which represents a 16.3% change from the previous report. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency, specifically in contrast to their industry peers', isn't encouraging. Consequently, their revenue efficiency received a grade of 43. Therefore, it received a score of 79.

Parameter Value Change Score
EBITDA -44.2 13.9% 90
Total Revenues 1.2 16.3% 43
Return on Equity -71.4 3.0% 65
* All values are TTM

The below chart describes Northwest Biotherapeutics's performance as reflected on its income statement with respect to its peers. While Northwest Biotherapeutics received a income statement score of 79 , the average of its peers stands on 70.0.

  •  NWBO
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Silence Therapeutics plc 313.4M 83 64 69 72 0 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 1 1
Amgen Inc. 130.1B 74 75 64 78 2 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 3 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 4 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 5 1
BioNTech SE 34.0B 41 89 75 79 6 1
Seagen Inc. 32.9B 54 65 70 62 7 1
Biogen Inc. 29.7B 90 57 73 70 8 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 9 1
Incyte Corporation 16.8B 59 77 60 73 10 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 11 1
United Therapeutics Corporation 10.6B 57 91 54 82 12 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 13 1
Exact Sciences Corporation 7.2B 57 67 54 62 14 1
Exelixis, Inc. 6.7B 54 91 54 81 15 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 16 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 17 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 18 1
Ascendis Pharma A/S 5.2B 38 68 46 54 19 1
Alkermes plc 5.0B 69 55 81 62 20 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 21 1
Novavax, Inc. 4.0B 41 89 54 75 22 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 23 1
Natera, Inc. 3.6B 52 51 78 52 24 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 25 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 26 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 27 1
CureVac N.V. 2.6B 45 83 71 74 28 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 29 1
Insmed Incorporated 2.4B 51 58 73 57 30 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 31 1
Abgenix Inc. 2.1B 47 47 47 47 32 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 33 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 34 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 35 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 36 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 37 1
Xencor, Inc. 1.6B 42 94 52 79 38 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 39 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 40 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 41 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 42 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 43 1
Veracyte, Inc. 1.4B 45 63 57 55 44 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 45 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 46 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 47 1
CareDx, Inc 1.2B 61 44 82 50 48 1
Vericel Corporation 1.1B 76 44 82 56 49 1
IVERIC bio, Inc. 1.1B 84 58 79 70 50 1
FibroGen, Inc. 1.0B 48 74 63 67 51 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 52 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 53 1
MannKind Corporation 957.2M 95 48 56 61 54 1
ImmunoGen, Inc. 946.1M 40 73 71 64 55 1
Merus N.V. 941.6M 48 60 59 54 56 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 57 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 58 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 59 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 60 1
Amarin Corporation plc 734.5M 95 44 82 63 61 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 62 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 63 1
CTI BioPharma Corp. 603.6M 84 50 62 59 64 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 65 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 66 1
AnaptysBio, Inc. 586.3M 97 50 77 68 67 1
Geron Corporation 566.2M 89 67 73 78 68 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 69 1
Immatics N.V. 538.7M 37 93 53 77 70 1
Agenus Inc. 520.5M 57 83 45 74 71 1
Radius Health, Inc. 499.8M 94 71 68 82 72 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 73 1
Vaxart, Inc. 440.0M 99 51 72 68 74 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 75 1
Affimed N.V. 415.0M 95 49 75 66 76 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 77 1
MiMedx Group, Inc. 391.5M 87 43 83 59 78 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 79 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 80 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 81 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 82 1
Zymeworks Inc. 324.7M 58 53 77 56 83 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 84 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 85 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 86 1
AC Immune SA 299.8M 83 61 65 70 87 1
Precigen, Inc. 299.1M 57 87 59 79 88 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 89 1
bluebird bio, Inc. 288.7M 99 91 61 96 90 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 91 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 92 1
MacroGenics, Inc. 184.6M 95 56 74 71 93 1
Chimerix, Inc. 178.4M 99 50 62 65 94 1
DermTech, Inc. 165.3M 49 48 78 52 95 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 96 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 97 1

Cash Flow Analysis

Overall, Northwest Biotherapeutics's critical cash flow metrics appear to signal strong support and a high likelihood of positive growth going forward. Northwest Biotherapeutics is doing a remarkable job of keeping its asset turnover under control. At filing, their asset turnover metrics were 0.0, representing a 34.6% change from the previous period. This metric might have a 4.1 percent impact on companies in the same industry and with the same market capitalization. Their impressive asset turnover metrics, specifically in contrast to their industry peers' performance, should support a tailwind in the company's stock price. The company's asset turnover movement, therefore, received a grade of 86. Also, Northwest Biotherapeutics's published capital expenditures (CapEx) numbers were encouraging and reflected management's balanced change strategy. Northwest Biotherapeutics recorded CapEx of -5.8, which represents 3.4% change from the previous report. The company appears to be headed in the right direction regarding resource allocation, exhibiting prudent capital expenditure growth compared to its peers. Consequently, their CapEx movement received a grade of 81. That said, one metric, Free Cash flow, stood out as strongly negative. Northwest Biotherapeutics did a poor job related to generating and maintaining strong free cash flow this period, which stood at -0.0, representing a 4.5% change from the previous filing. Companies in the same sector and market capitalization will usually be affected by up to 2.6 percent by this parameter. These free cash flow numbers show that management has not been executing well in generating critical cash flow while also encouraging growth. Its free cash flow movement, therefore, received a grade of 77. Consequently, the company's cash flow earned a score of 85.

Parameter Value Change Score
Net Cashflow -0.5 -109.7% 80
Capital Expenditure -5.8 3.4% 81
Asset Turnover 0.0 34.6% 86
Free Cashflow -0.0 4.5% 77
* All values are TTM

The below chart describes Northwest Biotherapeutics's performance as reflected on its cash flow with respect to its peers. While Northwest Biotherapeutics received a cash flow score of 85, the average of its peers stands on 71.0.

  •  NWBO
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Silence Therapeutics plc 313.4M 68 66 72 69 69 0 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 1 1
Amgen Inc. 130.1B 80 74 67 74 81 2 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 3 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 4 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 5 1
BioNTech SE 34.0B 73 97 50 52 72 6 1
Seagen Inc. 32.9B 53 53 50 87 58 7 1
Biogen Inc. 29.7B 58 54 90 73 66 8 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 9 1
Incyte Corporation 16.8B 78 79 92 74 84 10 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 11 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 12 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 13 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 14 1
Exelixis, Inc. 6.7B 79 90 89 83 87 15 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 16 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 17 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 18 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 19 1
Alkermes plc 5.0B 89 95 76 80 92 20 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 21 1
Novavax, Inc. 4.0B 62 38 63 54 60 22 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 23 1
Natera, Inc. 3.6B 52 54 56 84 58 24 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 25 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 26 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 27 1
CureVac N.V. 2.6B 87 80 90 70 90 28 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 29 1
Insmed Incorporated 2.4B 79 80 61 89 82 30 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 31 1
Abgenix Inc. 2.1B 66 53 45 59 58 32 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 33 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 34 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 35 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 36 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 37 1
Xencor, Inc. 1.6B 96 95 70 95 98 38 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 39 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 40 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 41 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 42 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 43 1
Veracyte, Inc. 1.4B 90 95 46 46 82 44 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 45 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 46 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 47 1
CareDx, Inc 1.2B 98 84 40 50 86 48 1
Vericel Corporation 1.1B 64 46 59 73 65 49 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 50 1
FibroGen, Inc. 1.0B 86 74 48 87 84 51 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 52 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 53 1
MannKind Corporation 957.2M 77 56 43 37 66 54 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 55 1
Merus N.V. 941.6M 70 71 74 53 71 56 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 57 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 58 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 59 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 60 1
Amarin Corporation plc 734.5M 52 40 74 55 55 61 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 62 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 63 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 64 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 65 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 66 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 67 1
Geron Corporation 566.2M 78 68 49 81 77 68 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 69 1
Immatics N.V. 538.7M 82 95 56 99 86 70 1
Agenus Inc. 520.5M 57 43 52 77 58 71 1
Radius Health, Inc. 499.8M 64 40 37 56 57 72 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 73 1
Vaxart, Inc. 440.0M 72 56 53 38 65 74 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 75 1
Affimed N.V. 415.0M 72 57 95 43 74 76 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 77 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 78 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 79 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 80 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 81 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 82 1
Zymeworks Inc. 324.7M 52 65 45 83 57 83 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 84 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 85 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 86 1
AC Immune SA 299.8M 66 77 79 63 68 87 1
Precigen, Inc. 299.1M 82 75 37 85 74 88 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 89 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 90 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 91 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 92 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 93 1
Chimerix, Inc. 178.4M 80 84 95 47 83 94 1
DermTech, Inc. 165.3M 60 51 45 86 58 95 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 96 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.